Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Employee Benefits

Surging demand for weight loss drugs runs into insurance claims denials

December 13, 2022 Reprints

Insurers are increasingly denying coverage for a new generation of U.S. Food and Drug Administration-approved diabetes drugs that can also help patients lose weight, Axios reports. Insurers have resisted paying for weight-loss drugs like Wegovy, which costs $1,300 a month, on the that presumption is obesity is a behavioral affliction, despite evidence it can be linked to hormonal factors and insulin resistance.

1. Ozempic side-effect litigation may surge
2. DeSantis pledges to overhaul ACA with new health plan
3. Weight-loss drugs drives health insurance fund $15M deficit
4. Some BCBS plans start offering direct health care delivery
5. Cigna and Humana in advanced merger talks
6. Cigna plans to sell Medicare Advantage business for Humana merger approval

Help

Surging demand for weight loss drugs runs into insurance claims denials

Readers Poll

Most Read in Employee Benefits

Sign up now for free access to this article and much more.

If you are already registered with Business Insurance, click here to Login

Please tell us a bit more about yourself in order to continue

About

Advertise

Reprints and Licensing

Resources